Trial Profile
Irbesartan in mild to moderate hypertensive patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2011
Price :
$35
*
At a glance
- Drugs Irbesartan (Primary) ; Irbesartan/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms I-SAVE
- Sponsors Sanofi
- 28 May 2008 Status changed from in progress to completed, according to ClinicalTrials.gov.
- 10 Apr 2008 The expected completion date for this trial is now 1 Jun 2008 as reported by ClinicalTrials.gov.
- 30 Oct 2006 Status change